Olysense Caddie - Flexible Endoscopy

Save up to 35% when trading in an Olympus ENDOAID OIP-1 when purchasing OLYSENSE CADDIE through NHS Supply Chain.

The Olympus OLYSENSE platform is a cloud based, integrated and adaptable digital endoscopy suite of seamlessly connected apps and solutions, that create a sophisticated, simple and scalable intelligent endoscopy ecosystem designed to aid in the early diagnosis of lower and upper gastrointestinal diseases. Connecting AI-driven endoscopy solutions with established Olympus equipment, OLYSENSE offers three cloud-based AI-driven software solutions, CADDIE™, CADU™ and SMARTIBD™ enabled with instant and automatic updates, ensuring the latest AI without requiring a service professional onsite to install software updates.

The CADDIE™ software solution assists endoscopists in detecting and characterising suspected colorectal polyps and potential early signs of colorectal cancer. The CADU™ software is designed to highlight areas with visual characteristics of dysplasia within Barrett’s Oesophagus. The SMARTIBD™ software, intended to be used for the purpose of assisting the assessment of disease activity for ulcerative colitis. All powered by the OLYSENSE Hub, connected to Olympus imaging equipment on the endoscopy tower. Receive a discount on our latest AI technology when trading in your ENDOAID OIP-1.

• CADDIE™ is a cloud-based, real-time AI solution designed to detect and characterise suspected colorectal polyps during colonoscopy procedures.
• Trained on a large, diverse dataset, CADDIE™ improves detection of difficult‑to‑identify lesions, including Sessile Serrated Lesions (SSLs) and flat polyps.
• Boosts adenoma detection rates, delivering a 7.4% increase in adenoma detection, helping improve early intervention and Colorectal Cancer (CRC) prevention.¹
• Significantly enhances detection of SSLs, enabling endoscopists to identify 230% more sessile serrated lesions compared with procedures without CADDIE™.²
• Improves recognition of flat, non‑polypoid lesions, with endoscopists detecting 37% more flat polyps when supported by the AI system.²
• Increases identification of high-risk polyp size categories, including 136% more large polyps and 93% more large adenomas compared to standard practice.²
• Supports real-time characterisation, enabling endoscopists to correctly characterise 13.3% more diminutive adenomas.¹
• Fully cloud‑based architecture removes the need for on‑site hardware, supporting rapid deployment and scalability across NHS endoscopy suites.
• Designed to assist clinicians without disrupting workflow, seamlessly integrating into standard endoscopic procedures.
• Backed by clinical evidence, including the CADDIE™ AI trial (NCT04325815)¹ and the multicentre EAGLE randomised controlled trial published in npj Digital Medicine (2025).²

References:
¹ Data on file with Odin Medical Ltd., CADDIE™ AI Trial – NCT04325815.
² Kader R, Hassan C, Lanas Á, et al. npj Digital Medicine, 26 Dec 2025. https://doi.org/10.1038/s41746-025-02270-1

This offer is over and above the standard discount available through the NHS Supply Chain framework agreement. The discount is a fixed term offer. All orders must be placed before 31 July 2026.